Drug Profile
Cutamesine
Alternative Names: AGY-94806; Cutamesine dihydrochloride; Msc-1; SA-4503Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Developer Ms Science; Santen Pharmaceutical
- Class Antidepressants; Neuroprotectants; Nootropics; Piperazines; Small molecules
- Mechanism of Action Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Retinitis pigmentosa
- Discontinued Major depressive disorder; Stroke; Vascular dementia
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in Japan (PO)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Retinitis-pigmentosa in Japan (Ophthalmic)
- 10 Mar 2014 Preclinical trials in Amyotrophic lateral sclerosis in Japan (PO)